Analyst Research

Report Title Price
Provider : Acquisdata
Provider : Stock Traders Daily
Provider : Thomson Reuters Stock Report
Provider : New Constructs, LLC

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Amgen announces Phase 3 ASPIRE trial of Kyprolis in patients with relapsed multiple myeloma met primary endpoint

Monday, 4 Aug 2014 07:30am EDT 

Amgen Inc:Says a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE (C A rfilzomib, Lenalidomide, and Dexametha S one versus Lenalidomide and Dexamethasone for the treatment of P at I ents with R elapsed Multiple My E loma) met its primary endpoint of progression-free survival (PFS).Patients treated with Kyprolis for Injection in combination with Revlimid and low-dose dexamethasone lived significantly longer without their disease worsening compared to patients treated with Revlimid and low-dose dexamethasone. 

Company Quote

25 Nov 2015